SCHEMBL28256337

SCHEMBL28256337

Clc1ccc(Oc2ccc(-c3nc4ccccc4[nH]3)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.66
RAB9A P51151 7/20 0.66
KDM4E B2RXH2 7/20 0.66
ALDH1A1 P00352 6/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
PKM P14618 2/20 0.66
CHEK2 O96017 5/20 0.61
GAA P10253 1/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
THRB P10828 1/20 0.60
HPGD P15428 3/20 0.58
TP53 P04637 2/20 0.58
MAPT P10636 2/20 0.58
HSD17B10 Q99714 2/20 0.58
POLB P06746 2/20 0.58
GFER P55789 1/20 0.58
DRD2 P14416 1/20 0.56
DRD3 P35462 1/20 0.56
MAPK13 O15264 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3417342 0.92 KDM4E (0.76) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL197619 0.91 RAB9A (0.72) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3335320 0.89 KDM4E (0.71) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL5636118 0.87 CHEK2 (0.63) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3916753 0.86 CHEK2 (0.65) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3367497 0.85 KDM4E (0.82) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL5634840 0.85 NPC1 (0.91) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2248110 0.85 SMN1; SMN2 (0.82) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3915300 0.85 CHEK2 (0.66) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4188962 0.84 MEN1 (0.76) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109790219-A Using lilotomab and177Lu-lilotomab satetraxetan treats non-Hodgkin lymphoma 诺帝克纳诺维科特公司 2019-05-21 CN disclosed
CN-109642905-A Using the method for the antibody in conjunction with C1 inactivated factor, the antibody in conjunction with c reactive protein and/or the antibody diagnosis in conjunction with complement component C4 and treating cancer 丹纳基因有限公司 2019-04-16 CN disclosed
CN-108939065-A Method for raising antigen presentation 诺帝克纳诺维科特公司 2018-12-07 CN disclosed